Clinical Trials & Pipeline
Mirna is a clinical-stage biopharmaceutical company developing a broad pipeline of leading microRNA-based oncology therapeutics, the first to demonstrate clinical proof of concept for microRNA replacement therapy.
LEARN MORE ABOUT US
MRX34, Mirna’s lead product candidate, is the first microRNA mimic to enter clinical testing.
LEARN MORE ABOUT OUR CLINICAL TRIALS AND PIPELINE
May 12, 2016
Mirna Therapeutics Reports First Quarter 2016 Financial Results and Program Updates
April 25, 2016
Mirna Therapeutics Appoints Vincent J. O’Neill, M.D., as Chief Medical Officer
VIEW ALL NEWS
© 2015 Mirna Therapeutics, Inc. All Rights Reserved.